The AscenD-LB study (NCT04001517) was a 91-patient, 16-week, double-blind placebo-controlled phase 2a clinical study in patients with mild-to-moderate probable DLB [dementia, with at least one core clinical feature of DLB and demonstrated abnormality in dopamine uptake by DaTscanTM (Ioflupane I123 SPECT), consistent with 2017 consensus clinical criteria29,30; see also Methods] and receiving cholinesterase inhibitor therapy (>3 months, stable dose >6 weeks). The gene discussed is BCHE; the disease is dementia.